跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
APO-DARIFENACIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
APO-DARIFENACIN
Authorized
STANDARD
APO-DARIFENACIN
Apotex Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
b7386aa52de1b43e
Company
Apotex Inc
Type
Standard
Approval Details
Approval Id
b7386aa52de1b43e
Drug Approval Canada Name
APO-DARIFENACIN
Product Name
APO-DARIFENACIN
Status
Marketed
Status Date
2021-07-28
Original Market Date
2021-07-28
Din
02452529
Drug Class
Human
Dosage Form
Tablet (Extended-Release)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
86:12.04
Atc Original
G04BD10 DARIFENACIN
Atc Name
g 04 bd 10
Aig Number
0151554002
Company Name
Apotex Inc
Company Address
150 Signet Drive, Toronto, Ontario, Canada, M9L 1T9
Company Detail Path
/organization/apotex-inc
Company Information
Pharmaceutical Company Name
Apotex Inc
Country Name
Canada
Province Name
Ontario
City Name
toronto,ontario,country_ca
Address
150 Signet Dr
Active Ingredients
DARIFENACIN (DARIFENACIN HYDROBROMIDE)
15 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
b7386aa52de1b43e
Type
Standard
Back to Health Canada Approvals